<DOC>
	<DOCNO>NCT03085992</DOCNO>
	<brief_summary>This study include patient affect advanced resectable rectal adenocarcinoma . It provide induction chemotherapy FOLFOXIRI regimen plus Bevacizumab follow Chemoradiotherapy plus Bevacizumab . Surgery total mesorectal incision must perform within 7-9 week last treatment . The protocol evaluate disease free survival two year . Translational analysis perform show presence VEGF polymorphism , CD133 surface marker colorectal CSCs .</brief_summary>
	<brief_title>Folfoxiri Plus Bevacizumab Followed Chemoradiotherapy Plus Bevacizumab Patients With Resectable Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically proven diagnosis rectal adenocarcinoma . Diagnosis obtain biopsy technique leave major portion tumor intact . Locally advanced , resectable disease define presence least one follow feature : tumour extend within 1 mm beyond mesorectal fascia ( ie , circumferential radial margin threaten involve ) ; low third ( ≤ 6 cm anal verge ) cT3 tumour ; tumour extend 5 mm perirectal fat ; T4 tumour ( ie , invade surround structure peritoneum ) ; clinical stage III disease ( T14 , N12 ) , definition clinically positive lymph node node ≥ 1.0 cm ; Distal border tumor must locate &lt; 12 cm anal verge . No evidence metastatic disease CT scan chest abdomen total body PETCT scan . Tumor must amenable curative resection ( curative resection include pelvic exenteration ) . No history invasive rectal malignancy , regardless diseasefree interval . No rectal cancer ( i.e. , sarcoma , lymphoma , carcinoid , squamous cell carcinoma , cloacogenic carcinoma ) synchronous colon cancer . No clear indication involvement pelvic side wall image . Age 18 75 year . ECOG Performance status &lt; 2 age &lt; 70 year = 0 age 7175 year . Life expectancy least 5 year ( exclude diagnosis cancer ) . Hematopoietic : absolute neutrophil count ≥ 1,000/mm3 ; platelet count ≥ 100,000/mm3 ; haemoglobin level ≥ 10 g/dL . Hepatic : total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ; alkaline phosphatase ≤ 2 time ULN ; AST ≤ 2 time ULN . [ Note : *If AST &gt; ULN , serologic test Hepatitis B C must negative ] . Renal : creatinine clearance &gt; 50 mL/min ; renal disease would preclude study treatment followup . Written inform consent experimental treatment pharmacogenomic analysis . Previous treatment oxaliplatin , irinotecan bevacizumab . Previous 5fluorouracil capecitabine treatment allow . Previous pelvic radiation therapy . Hepatic disease would preclude study treatment followup ; uncontrolled coagulopathy ; history viral hepatitis chronic liver disease . Cardiovascular disease would preclude study treatment followup ; New York Heart Association class III IV heart disease ; active ischemic heart disease ; myocardial infarction within past 6 month ; symptomatic arrhythmia ; uncontrolled hypertension . Lack upper gastrointestinal tract integrity malabsorption syndrome ; active inflammatory bowel disease ( i.e. , patient require current medical intervention symptomatic ) . Pregnant lactating woman . Fertile patient must use effective contraception ( i.e doublebarrier contraceptive measure , oral contraception avoidance intercourse study 30 day surgery ) . Patients prior malignancy ( exception rectal cancer ) , include invasive colon cancer , eligible provide diseasefree ≥ 5 year deem physician low risk recurrence . Other malignancy within past 5 year exception effectively treat squamous cell basal cell skin cancer , melanoma situ , carcinoma situ cervix , carcinoma situ colon rectum . Known hypersensitivity fluorouracil , oxaliplatin irinotecan Chinese hamster ovary cell protein . Clinically significant peripheral neuropathy ( i.e. , neurosensory neuromotor toxicity ≥ grade 2 ) . Psychiatric addictive disorder , condition , opinion investigator , would preclude study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>rectal cancer</keyword>
	<keyword>FOLFOXIRI</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>trust</keyword>
</DOC>